PureLift Pro Max
Xtreem Pulse, LLC · Decision date Sep 11, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for PureLift Pro Max, a transcutaneous electrical stimulator for aesthetic purposes, on September 11, 2026, under 510(k) number K262861. The applicant is Xtreem Pulse, LLC, and the application was received August 13, 2026. The product code is NFO, regulation number 882.5890, with neurology as the regulation medical specialty and review panel. SESE indicates clearance of this 510(k), not premarket approval of the device.
The available decision document describes a comparison involving a 2.8 mA (10 kΩ) parameter, judged different but technologically equivalent, with the stated conclusion that the difference does not raise a different question of safety or effectiveness. The document also references a predicate described as an FDA-cleared NFO cosmetic electrical stimulation device and a regulation name for a transcutaneous electrical nerve stimulator for pain relief. The source does not identify the predicate's 510(k) number, the specific changed component, or the full indications cleared for PureLift Pro Max; those details remain unknown here.
No clinical performance data, adverse event information or labeling text is present in the public information, so no efficacy or safety conclusions are drawn.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Neurology
- Decision date
- Sep 11, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262861
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Xtreem Pulse, LLC
- Product code
- NFO
- Decision code
- SESE
- Decision date
- Sep 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, Transcutaneous Electrical, Aesthetic Purposes.
- Applicant
- Xtreem Pulse, LLC
- Product code
- NFO
- FDA device class
- 2
FDA decision timeline
K262861 received
Application receipt date recorded by FDA.
K262861 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code NFO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
FAQ (FAQ 401);FAQ (FAQ 402)K261625 | Foreo, Inc. | 510(k) clearance | Oct 26, 2026 | FDA |
FAQ (FAQ 411)K261565 | Foreo, Inc. | 510(k) clearance | Oct 22, 2026 | FDA |
| Guangdong Newdermo Biotech Co., Ltd. | 510(k) clearance | Sep 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Xtreem Pulse, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- New York, NY
Sources and methodology
- Original FDA record: K262861
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
